Drug Profile
Onilcamotide - CHOSA Oncology
Alternative Names: Rhoc-peptide-vaccine-RV001V; RV-001; RV-001V; RV001V - CHOSA OncologyLatest Information Update: 01 Mar 2023
Price :
$50
*
At a glance
- Originator RhoVac
- Developer CHOSA Oncology; Mount Sinai Health System
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Prostate cancer
Most Recent Events
- 15 Feb 2023 RhoVac is now called CHOSA Oncology
- 28 Sep 2022 Phase II development for Prostate cancer (Late-stage disease, Recurrent) is ongoing in Finland, United Kingdom, Germany, Sweden, USA, Belgium (SC) (RhoVac pipeline, September 2022)
- 29 May 2022 Efficacy data from the BraVac phase IIb Prostate cancer trial released by RhoVac